Telmisartan + CilnidipineThird Party Manufacturing in India

Telmisartan + Cilnidipine works through a synergetic dual mechanism that combines receptor blockade with calcium entry inhibition. Telmisartan blocks the AT1 receptors, while Cilnidipine uniquely inhibits both L-type calcium channels on vascular smooth muscle and N-type calcium channels on sympathetic nerve terminals. It targets these receptors to help the body lower systemic blood pressure while suppressing reflex tachycardia and reducing renal capillary pressure. Unlike standard calcium channel blockers, this combined approach minimizes ankle edema. It is highly effective and well-tolerated.

Therapeutic Uses

• Hypertension with Tachycardia: Ideal for patients whose elevated blood pressure is accompanied by elevated heart rates or sympathetic overactivity.
• Renal-Protective Antihypertensive Care: Prevents glomerular hyperfiltration, making it highly valuable for hypertensive individuals with early kidney strain.
• Vascular Endothelial Protection: Enhances nitric oxide bioavailability to reduce arterial stiffness over time.

Why Manufacturers Choose Telmisartan + Cilnidipine

Telmisartan + Cilnidipine third party manufacturing in India is seeing rapid adoption due to Cilnidipine's superior safety profile regarding pedal edema compared to older agents. This combination requires specialized handling to protect both components from moisture degradation. Our partner facilities leverage advanced, temperature-monitored manufacturing suites operating under strict WHO-GMP protocols, ensuring long-term product stability and rapid batch turnaround for corporate distributors.